{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T16:41:23Z","timestamp":1791996083306,"version":"4.4.0"},"reference-count":35,"publisher":"SAGE Publications","issue":"8","license":[{"start":{"date-parts":[[2021,8,1]],"date-time":"2021-08-01T00:00:00Z","timestamp":1627776000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Microbial Drug Resistance"],"published-print":{"date-parts":[[2021,8]]},"abstract":"<jats:sec>\n                    <jats:title>Aims:<\/jats:title>\n                    <jats:p>\n                      Several\n                      <jats:italic toggle=\"yes\">in vitro<\/jats:italic>\n                      and\n                      <jats:italic toggle=\"yes\">in vivo<\/jats:italic>\n                      studies demonstrated that adding a \u03b2-lactam to vancomycin (VAN) or daptomycin (DAP) can provide synergy against methicillin-resistant\n                      <jats:italic toggle=\"yes\">Staphylococcus aureus<\/jats:italic>\n                      (MRSA). However, the results from clinical studies were controversial. The objective of this systematic review and meta-analysis was to compare the efficacy and safety of using VAN or DAP plus a \u03b2-lactam (combination therapy) and using VAN or DAP alone (monotherapy) in MRSA bloodstream infections.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods:<\/jats:title>\n                    <jats:p>We included randomized controlled trials and observational studies evaluating whether combination therapy can improve clinical and microbiological outcomes and safety compared to monotherapy with VAN or DAP in MRSA-related bacteremia.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>Literature search identified 3 randomized clinical trials and 10 observational studies involving at least 1,796 patients. There were no significant associations between the combination therapy and risk of mortality within 30 days (risk ratios [RRs], 1.10, 95% confidence interval [CI], 0.82\u20131.46), in-hospital mortality (RR, 0.59, 95% CI, 0.31\u20131.13) and mortality within 60\u201390 days (RR, 0.91, 95% CI, 0.64\u20131.29). There was also no evidence that there was a difference in length of hospital stay between the combination therapy and monotherapy (mean difference, \u22120.41 days, 95% CI, \u22123.41 to 2.59). However, compared with monotherapy, combination therapy seemed to have a shorter duration of bacteremia(mean difference, \u22121.06 days, 95% CI, \u22121.53 to \u22120.60), a lower risk of persistent bacteremia (RR, 0.63, 95% CI, 0.51\u20130.79) and a lower risk of bacteremia recurrence within 60\u201390 days (RR, 0.61, 95% CI, 0.40\u20130.92). There were no statistically significant differences in the total number of adverse events, including acute kidney injury (AKI) (RR, 1.52, 95% CI, 0.84\u20132.73), thrombocytopenia (RR, 1.13, 95% CI, 0.74\u20131.73), and diarrhea (RR, 1.36, 95% CI, 0.70\u20132.65), between patients with combination therapy and monotherapy. In subgroup analysis, when the analysis was limited to the studies comparing using DAP plus ceftaroline with monotherapy, we found that the former had a lower risk of mortality within 30 days. In addition, a subgroup analysis limited to randomized clinical trials showed that the combination therapy was associated with a higher risk of AKI compared with using VAN or DAP alone.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions:<\/jats:title>\n                    <jats:p>Although adding a \u03b2-lactam to standard therapy seemed to experience a higher clearance compared with monotherapy in patients with MRSA bacteremia, the combination therapy did not increase survival benefits. Based on the available evidence, the combination therapy was not supported as the routine management of MRSA-related bacteremia, and both its harms and benefits should be taken into account.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1089\/mdr.2020.0350","type":"journal-article","created":{"date-parts":[[2021,3,17]],"date-time":"2021-03-17T11:39:58Z","timestamp":1615981198000},"page":"1044-1056","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":16,"title":["Vancomycin or Daptomycin Plus a \u03b2-Lactam Versus Vancomycin or Daptomycin Alone for Methicillin-Resistant\n                    <i>Staphylococcus aureus<\/i>\n                    Bloodstream Infections: A Systematic Review and Meta-Analysis"],"prefix":"10.1177","volume":"27","author":[{"given":"Yi-Hu","family":"Yi","sequence":"first","affiliation":[{"name":"Department of Orthopaedics, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiang-Lin","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Third Xiangya Hospital, Central South University, Changsha, China."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wen-Jun","family":"Yin","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Third Xiangya Hospital, Central South University, Changsha, China."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei-Hua","family":"Xu","sequence":"additional","affiliation":[{"name":"Department of Orthopaedics, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2021,8,12]]},"reference":[{"key":"e_1_3_4_2_2","first-page":"1309","volume":"382","author":"Jernigan J.A.","year":"2020","unstructured":"Jernigan J.A., , Hatfield K.M, , Wolford H., , Nelson R.E, , Olubajo B., , Reddy S.C, , McCarthy N., , Paul P., , McDonald L.C, , Kallen A., , Fiore A., , Craig M., , and Baggs J.. 2020. Multidrug-resistant bacterial infections in U.S. hospitalized patients, 2012\u20132017. N. Engl. J. Med. 382:1309\u20131319.","journal-title":"Multidrug-resistant bacterial infections in U.S. hospitalized patients, 2012\u20132017. N. Engl. J. Med"},{"key":"e_1_3_4_3_2","doi-asserted-by":"crossref","first-page":"1463","DOI":"10.1016\/S0025-6196(11)61088-4","article-title":"Methicillin-resistant Staphylococcus aureus: the latest health scare","volume":"82","author":"Sampathkumar P.","year":"2007","unstructured":"Sampathkumar P. 2007. Methicillin-resistant Staphylococcus aureus: the latest health scare. Mayo Clin. Proc. 82:1463\u20131467.","journal-title":"Mayo Clin. Proc"},{"key":"e_1_3_4_4_2","doi-asserted-by":"crossref","first-page":"214","DOI":"10.15585\/mmwr.mm6809e1","article-title":"Vital signs: epidemiology and recent trends in methicillin-resistant and in methicillin-susceptible Staphylococcus aureus bloodstream infections-United States","volume":"68","author":"Kourtis A.P.","year":"2019","unstructured":"Kourtis A.P., , Hatfield K., , Baggs J., , Mu Y., , See I., , Epson E., , Nadle J., , Kainer M.A, , Dumyati G., , Petit S., , Ray SM, , Emerging Infections Program MAuthor Group RSA, , Ham D., , Capers C., , Ewing H., , Coffin N., , McDonald L.C, , Jernigan J., , and Cardo D.. 2019. Vital signs: epidemiology and recent trends in methicillin-resistant and in methicillin-susceptible Staphylococcus aureus bloodstream infections-United States. MMWR Morb. Mortal. Wkly. Rep. 68:214\u2013219.","journal-title":"MMWR Morb. Mortal. Wkly. Rep"},{"key":"e_1_3_4_5_2","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciz498"},{"key":"e_1_3_4_6_2","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1016\/j.jinf.2018.08.015","article-title":"Survival following Staphylococcus aureus bloodstream infection: a prospective multinational cohort study assessing the impact of place of care","volume":"77","author":"Nambiar K.","year":"2018","unstructured":"Nambiar K., , Seifert H., , Rieg S., , Kern W.V, , Scarborough M., , Gordon N.C, , Kim H.B, , Song K.H, , Tilley R., , Gott H., , Liao C.H, , Edgeworth J., , Nsutebu E., , L\u00f3pez-Cort\u00e9s L.E, , Morata L., , Walker A.S, , Thwaites G., , Llewelyn M.J, , and Kaasch A.J.. 2018. Survival following Staphylococcus aureus bloodstream infection: a prospective multinational cohort study assessing the impact of place of care. J. Infect. 77:516\u2013525.","journal-title":"J. Infect"},{"key":"e_1_3_4_7_2","doi-asserted-by":"publisher","DOI":"10.1128\/CMR.00134-14"},{"key":"e_1_3_4_8_2","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciq146"},{"key":"e_1_3_4_9_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa053783"},{"key":"e_1_3_4_10_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01525-12"},{"key":"e_1_3_4_11_2","doi-asserted-by":"crossref","first-page":"1334","DOI":"10.1016\/j.clinthera.2014.06.027","article-title":"Vancomycin and piperacillin-tazobactam against methicillin-resistant Staphylococcus aureus and vancomycin-intermediate Staphylococcus aureus in an in vitro pharmacokinetic\/pharmacodynamic model","volume":"36","author":"Dilworth T.J.","year":"2014","unstructured":"Dilworth T.J., , Leonard S.N, , Vilay A.M, , and Mercier R.C.. 2014. Vancomycin and piperacillin-tazobactam against methicillin-resistant Staphylococcus aureus and vancomycin-intermediate Staphylococcus aureus in an in vitro pharmacokinetic\/pharmacodynamic model. Clin. Ther. 36:1334\u20131344.","journal-title":"Clin. Ther"},{"key":"e_1_3_4_12_2","first-page":"1028","volume":"58","author":"Dilworth T.J.","year":"2014","unstructured":"Dilworth T.J., , Sliwinski J., , Ryan K., , Dodd M., , and Mercier R.C.. 2014. Evaluation of vancomycin in combination with piperacillin-tazobactam or oxacillin against clinical methicillin-resistant Staphylococcus aureus isolates and vancomycin-intermediate S. aureus isolates in vitro. Antimicrob. Agents Chemother. 58:1028\u20131033.","journal-title":"Evaluation of vancomycin in combination with piperacillin-tazobactam or oxacillin against clinical methicillin-resistant Staphylococcus aureus isolates and vancomycin-intermediate S. aureus isolates in vitro. Antimicrob. Agents Chemother"},{"key":"e_1_3_4_13_2","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1080\/23744235.2016.1277587","article-title":"A combination of ceftaroline and daptomycin has synergistic and bactericidal activity in vitro against daptomycin nonsusceptible methicillin-resistant Staphylococcus aureus (MRSA)","volume":"49","author":"Shafiq I.","year":"2017","unstructured":"Shafiq I., , Bulman Z.P, , Spitznogle S.L, , Osorio J.E, , Reilly I.S, , Lesse A.J, , Parameswaran G.I, , Mergenhagen K.A, , and Tsuji B.T.. 2017. A combination of ceftaroline and daptomycin has synergistic and bactericidal activity in vitro against daptomycin nonsusceptible methicillin-resistant Staphylococcus aureus (MRSA). Infect. Dis. (Lond), 49:410\u2013416.","journal-title":"Infect. Dis. (Lond)"},{"key":"e_1_3_4_14_2","doi-asserted-by":"publisher","DOI":"10.1055\/s-0034-1396906"},{"key":"e_1_3_4_15_2","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1038\/ja.2017.7","article-title":"Synergistic effects of vancomycin and beta-lactams against vancomycin highly resistant Staphylococcus aureus","volume":"70","author":"Tabuchi F.","year":"2017","unstructured":"Tabuchi F., , Matsumoto Y., , Ishii M., , Tatsuno K., , Okazaki M., , Sato T., , Moriya K., , and Sekimizu K.. 2017. Synergistic effects of vancomycin and beta-lactams against vancomycin highly resistant Staphylococcus aureus. J Antibiot. (Tokyo), 70:771\u2013774.","journal-title":"J Antibiot. (Tokyo)"},{"key":"e_1_3_4_16_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00109-013-1100-7"},{"key":"e_1_3_4_17_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2020.0103"},{"key":"e_1_3_4_18_2","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/civ808"},{"key":"e_1_3_4_19_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.02483-18"},{"key":"e_1_3_4_20_2","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciz746"},{"key":"e_1_3_4_21_2","doi-asserted-by":"publisher","DOI":"10.1002\/phar.2034"},{"key":"e_1_3_4_22_2","doi-asserted-by":"publisher","DOI":"10.1007\/s40121-020-00292-8"},{"key":"e_1_3_4_23_2","doi-asserted-by":"crossref","first-page":"e01554","DOI":"10.1128\/AAC.01554-17","article-title":"Outcomes of vancomycin plus a beta-lactam versus vancomycin only for treatment of methicillin-resistant Staphylococcus aureus bacteremia","volume":"62","author":"Truong J.","year":"2018","unstructured":"Truong J., , Veillette J.J, , and Forland S.C.. 2018. Outcomes of vancomycin plus a beta-lactam versus vancomycin only for treatment of methicillin-resistant Staphylococcus aureus bacteremia. Antimicrob. Agents Chemother. 62:e01554-17.","journal-title":"Antimicrob. Agents Chemother"},{"key":"e_1_3_4_24_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01204-13"},{"key":"e_1_3_4_25_2","doi-asserted-by":"crossref","first-page":"ofz538","DOI":"10.1093\/ofid\/ofz538","article-title":"Multicenter cohort of patients with methicillin-resistant Staphylococcus aureus bacteremia receiving daptomycin plus ceftaroline compared with other MRSA treatments","volume":"7","author":"McCreary E.K.","year":"2020","unstructured":"McCreary E.K., , Kullar R., , Geriak M., , Zasowski E.J, , Rizvi K., , Schulz L.T, , Ouellette K., , Vasina L., , Haddad F., , Rybak M.J, , Zervos M.J, , Sakoulas G., , and Rose W.E.. 2020. Multicenter cohort of patients with methicillin-resistant Staphylococcus aureus bacteremia receiving daptomycin plus ceftaroline compared with other MRSA treatments. Open Forum Infect. Dis. 7:ofz538.","journal-title":"Open Forum Infect. Dis"},{"key":"e_1_3_4_26_2","doi-asserted-by":"publisher","DOI":"10.1176\/appi.ajp.2018.17111194"},{"key":"e_1_3_4_27_2","doi-asserted-by":"publisher","DOI":"10.1177\/0962280216669183"},{"key":"e_1_3_4_28_2","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2288-14-135"},{"key":"e_1_3_4_29_2","first-page":"S318","article-title":"Daptomycin\/ceftaroline in combination vs","volume":"1","author":"Fox M.","year":"2018","unstructured":"Fox M., , Zeqollari K., , Lee G., , Pontiggia L., , Byrne D., , Adams J., , King M., , and Rose L.. 2018. Daptomycin\/ceftaroline in combination vs. vancomycin for the treatment of methicillin-resistant Staphylococcus aureus bacteremia. Open Forum Infect. Dis. 5(Suppl, 1):S318.","journal-title":"vancomycin for the treatment of methicillin-resistant Staphylococcus aureus bacteremia. Open Forum Infect. Dis. 5(Suppl"},{"key":"e_1_3_4_30_2","doi-asserted-by":"crossref","first-page":"S281","DOI":"10.1093\/ofid\/ofx163.631","article-title":"Combination vancomycin\/cefazolin (VAN\/cfz) for methicillin-resistant Staphylococcus aureus (MRSA) bloodstream infections (BSI)","volume":"1","author":"Trinh T.D.","year":"2017","unstructured":"Trinh T.D., , Zasowski E.J, , Lagnf A.M, , Bhatia S., , Dhar S., , Mynatt R., , Pogue J.M, , and Rybak M.J.. 2017. Combination vancomycin\/cefazolin (VAN\/cfz) for methicillin-resistant Staphylococcus aureus (MRSA) bloodstream infections (BSI). Open Forum Infect. Dis. 4(Suppl, 1):S281.","journal-title":"Open Forum Infect. Dis. 4(Suppl"},{"key":"e_1_3_4_31_2","doi-asserted-by":"crossref","first-page":"S769","DOI":"10.1093\/ofid\/ofz360.1928","article-title":"Combination vancomycin plus cefazolin for methicillin-resistant Staphylococcus aureus bloodstream infections","volume":"2","author":"Jorgensen S.C.J.","year":"2019","unstructured":"Jorgensen S.C.J., , Trinh T.D, , Zasowski E.J, , Alosaimy S., , Melvin S., , Bhatia S., , Dhar S., , Mynatt R.P, , Pogue J.M, , and Rybak M.J.. 2019. Combination vancomycin plus cefazolin for methicillin-resistant Staphylococcus aureus bloodstream infections. Open Forum Infect. Dis. 6(Suppl, 2):S769.","journal-title":"Open Forum Infect. Dis. 6(Suppl"},{"key":"e_1_3_4_32_2","doi-asserted-by":"crossref","first-page":"ofz079","DOI":"10.1093\/ofid\/ofz079","article-title":"The impact of concomitant empiric cefepime on patient outcomes of methicillin-resistant Staphylococcus aureus bloodstream infections treated with vancomycin","volume":"6","author":"Zasowski E.J.","year":"2019","unstructured":"Zasowski E.J., , Trinh T.D, , Atwan S.M, , Merzlyakova M., , Langf A.M, , Bhatia S., , and Rybak M.J.. 2019. The impact of concomitant empiric cefepime on patient outcomes of methicillin-resistant Staphylococcus aureus bloodstream infections treated with vancomycin. Open Forum Infect. Dis. 6:ofz079.","journal-title":"Open Forum Infect. Dis"},{"key":"e_1_3_4_33_2","first-page":"S319","article-title":"Adjuvant beta-lactam therapy combined with vancomycin for methicillin-resistant Staphylococcus aureus (mRSA) bacteremia: does beta-lactam class matter? Open Forum Infect","volume":"1","author":"Dilworth T.J.","year":"2018","unstructured":"Dilworth T.J., , Casapao A.M, , Ibrahim O.M, , Jacobs D.M, , Bowers D.R, , Beyda N.D, , and Mercier R.C.. 2018. Adjuvant beta-lactam therapy combined with vancomycin for methicillin-resistant Staphylococcus aureus (mRSA) bacteremia: does beta-lactam class matter? Open Forum Infect. Dis. 5(Suppl, 1):S319.","journal-title":"Dis. 5(Suppl"},{"key":"e_1_3_4_34_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.clinthera.2014.09.005"},{"key":"e_1_3_4_35_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01586-12"},{"key":"e_1_3_4_36_2","doi-asserted-by":"publisher","DOI":"10.1681\/ASN.2018121223"}],"container-title":["Microbial Drug Resistance"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1089\/mdr.2020.0350","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1089\/mdr.2020.0350","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1089\/mdr.2020.0350","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T20:38:30Z","timestamp":1777667910000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/full\/10.1089\/mdr.2020.0350"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,8]]},"references-count":35,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2021,8]]}},"alternative-id":["10.1089\/mdr.2020.0350"],"URL":"https:\/\/doi.org\/10.1089\/mdr.2020.0350","relation":{},"ISSN":["1076-6294","1931-8448"],"issn-type":[{"value":"1076-6294","type":"print"},{"value":"1931-8448","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,8]]}}}